AIRLINK 189.52 Decreased By ▼ -0.64 (-0.34%)
BOP 12.77 Decreased By ▼ -0.06 (-0.47%)
CNERGY 7.16 Decreased By ▼ -0.05 (-0.69%)
FCCL 42.12 Decreased By ▼ -1.29 (-2.97%)
FFL 15.54 Increased By ▲ 0.15 (0.97%)
FLYNG 25.19 Decreased By ▼ -1.18 (-4.47%)
HUBC 130.09 Decreased By ▼ -0.52 (-0.4%)
HUMNL 14.32 Increased By ▲ 0.48 (3.47%)
KEL 4.67 Decreased By ▼ -0.04 (-0.85%)
KOSM 6.51 Decreased By ▼ -0.19 (-2.84%)
MLCF 46.94 Decreased By ▼ -2.57 (-5.19%)
OGDC 202.75 Decreased By ▼ -2.06 (-1.01%)
PACE 6.44 Increased By ▲ 0.03 (0.47%)
PAEL 41.14 Increased By ▲ 0.33 (0.81%)
PIAHCLA 17.03 Increased By ▲ 0.18 (1.07%)
PIBTL 8.71 Increased By ▲ 0.02 (0.23%)
POWER 10.70 Decreased By ▼ -0.32 (-2.9%)
PPL 172.21 Decreased By ▼ -2.23 (-1.28%)
PRL 34.77 Increased By ▲ 0.06 (0.17%)
PTC 24.85 Decreased By ▼ -0.14 (-0.56%)
SEARL 96.72 Decreased By ▼ -1.27 (-1.3%)
SILK 1.10 Increased By ▲ 0.01 (0.92%)
SSGC 30.58 Decreased By ▼ -0.52 (-1.67%)
SYM 17.89 Increased By ▲ 0.08 (0.45%)
TELE 8.40 Increased By ▲ 0.10 (1.2%)
TPLP 11.89 Decreased By ▼ -0.29 (-2.38%)
TRG 63.35 Increased By ▲ 1.69 (2.74%)
WAVESAPP 11.63 Decreased By ▼ -0.04 (-0.34%)
WTL 1.50 Increased By ▲ 0.02 (1.35%)
YOUW 4.05 Decreased By ▼ -0.13 (-3.11%)
AIRLINK 189.52 Decreased By ▼ -0.64 (-0.34%)
BOP 12.77 Decreased By ▼ -0.06 (-0.47%)
CNERGY 7.16 Decreased By ▼ -0.05 (-0.69%)
FCCL 42.12 Decreased By ▼ -1.29 (-2.97%)
FFL 15.54 Increased By ▲ 0.15 (0.97%)
FLYNG 25.19 Decreased By ▼ -1.18 (-4.47%)
HUBC 130.09 Decreased By ▼ -0.52 (-0.4%)
HUMNL 14.32 Increased By ▲ 0.48 (3.47%)
KEL 4.67 Decreased By ▼ -0.04 (-0.85%)
KOSM 6.51 Decreased By ▼ -0.19 (-2.84%)
MLCF 46.94 Decreased By ▼ -2.57 (-5.19%)
OGDC 202.75 Decreased By ▼ -2.06 (-1.01%)
PACE 6.44 Increased By ▲ 0.03 (0.47%)
PAEL 41.14 Increased By ▲ 0.33 (0.81%)
PIAHCLA 17.03 Increased By ▲ 0.18 (1.07%)
PIBTL 8.71 Increased By ▲ 0.02 (0.23%)
POWER 10.70 Decreased By ▼ -0.32 (-2.9%)
PPL 172.21 Decreased By ▼ -2.23 (-1.28%)
PRL 34.77 Increased By ▲ 0.06 (0.17%)
PTC 24.85 Decreased By ▼ -0.14 (-0.56%)
SEARL 96.72 Decreased By ▼ -1.27 (-1.3%)
SILK 1.10 Increased By ▲ 0.01 (0.92%)
SSGC 30.58 Decreased By ▼ -0.52 (-1.67%)
SYM 17.89 Increased By ▲ 0.08 (0.45%)
TELE 8.40 Increased By ▲ 0.10 (1.2%)
TPLP 11.89 Decreased By ▼ -0.29 (-2.38%)
TRG 63.35 Increased By ▲ 1.69 (2.74%)
WAVESAPP 11.63 Decreased By ▼ -0.04 (-0.34%)
WTL 1.50 Increased By ▲ 0.02 (1.35%)
YOUW 4.05 Decreased By ▼ -0.13 (-3.11%)
BR100 11,865 Decreased By -96.2 (-0.8%)
BR30 35,321 Decreased By -314 (-0.88%)
KSE100 112,801 Decreased By -938.2 (-0.82%)
KSE30 35,036 Decreased By -291.2 (-0.82%)
Business & Finance

Swiss drugmaker Novartis to help make Pfizer-Biontech COVID-19 vaccine

  • Three vaccines from Western companies Pfizer-Biontech, AstraZeneca and Moderna have been approved by regulators.
  • Novartis has been mobilizing on multiple fronts to support the global pandemic response.
Published January 29, 2021

ZURICH: Swiss drugmaker Novartis has signed an initial agreement to provide manufacturing capacity for Pfizer and Biontech's COVID-19 vaccine, a move aimed at helping boost production as supplies fall shy of demand.

Subject to reaching a final agreement, Novartis plans to commence production in the second quarter of 2021, the Basel-based company said on Friday, adding it would use manufacturing facilities at its site in Stein, Switzerland, near the Rhine River on the German border.

Three vaccines from Western companies Pfizer-Biontech, AstraZeneca and Moderna have been approved by regulators, but limited production and delayed deliveries have hampered efforts to quickly vaccinate people most at risk for COVID-19.

Novartis's announcement that it was joining the push to remedy the shortfall follows a move by Sanofi this week to work with Biontech to supply 125 million doses of its mRNA vaccine to the European Union.

"Novartis has been mobilizing on multiple fronts to support the global pandemic response," said Steffen Lang, head of Novartis Technical Operations.

Novartis, which did not give specifics on how much drug substance it would produce for Pfizer-Biontech if the deal goes through, added it is in "advanced discussions" with additional companies to take on production of mRNA, therapeutic protein and other raw materials for vaccines and therapeutics.

Comments

Comments are closed.